Trivalent influenza vaccine (contains B/Yamagata strain)

BIOLOGICAL2 trials

Sponsors

Sinovac Biotech Co., Ltd

Conditions

Seasonal Influenza

Phase 3

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (15µg/0.5ml)

CompletedNCT03853993

Sinovac Biotech Co., LtdSeasonal Influenza

Start: 2018-01-23End: 2018-10-08Updated: 2019-02-27

Clinical Trial to Evaluate the Safety and Immunogenicity of Quadrivalent Influenza Vaccine (7.5μg/0.25ml)

CompletedNCT03859141

Sinovac Biotech Co., LtdSeasonal Influenza

Start: 2018-02-06End: 2018-11-02Updated: 2019-03-01

Related Papers

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: A randomized, double-blind, controlled phase III study in healthy population aged ≥3 years.

2020-07-2711 citations

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China

Human Vaccines & Immunotherapeutics2020-04-2917 citations